Originator
Eutonyl, Abbott , US ,1963
Manufacturing Process
A mixture of 23.8 grams (0.2 mol) of propargyl bromide, 24.2 grams (0.2 mol) of N-methylbenzylamine and 400 ml of anhydrous ethanol in the presence of 42.4 grams (0.4 mol) of anhydrous sodium carbonate was heated at the boiling temperature and under reflux for a period of 17 hours.
The sodium carbonate was then removed by filtration and the alcohol was removed by distillation under reduced pressure. The residue was treated with 300 ml of dry ether and the resulting solution was filtered to remove sodium bromide.
The filtrate was dried and fractionally distilled under reduced pressure to obtain the desired N-methyl-N-propargylbenzylamine which boiled at 96°97°C at 11 mm pressure.
Analysis calculated for C11H13N: C = 82.97%; H = 8.23%; N = 8.80%. Found: C = 82.71%; H = 8.51%; N = 8.93%.
The hydrochloride salt of this amine was prepared by dissolving the amine in ether and adding ethereal hydrogen chloride to the ether solution. The solid hydrochloride salt which precipitated was recrystallized from an ethanol-ether mixture and was found to melt at 154° - 155°C.
Enzyme inhibitor
This antihypertensive agent (FWfree-base = 159.23 g/mol; CAS 555-57-7), also known as Eutonyl, N-benzyl-N-methyl-2-propynylamine, is amechanism-based inhibitor that targets monoamine oxidase, beginning with an initial reversible interaction (Ki = 4-5 μM) and proceeding to irreversible loss of enzyme activity. Target(s): aldehyde dehydrogenase, pargyline is the precursor of the actual inhibitor; bacterial bioluminescence; and monoamine oxidase.
